Transgene Reports 2015 Financial Results and Provides Outlook for 2016

le
0
Transgene Reports 2015 Financial Results and Provides Outlook for 2016

• Solid financial position:
- 2015 year-end cash available of ?31.7 million, plus up to ?30 million in additional financing secured in January 2016

• Implementation of new development strategy underway:
- Ambitious development plan with Transgene’s immunotherapy product candidates in combination with immune checkpoint inhibitors

Conference call and webcast (in English) March 9 at 2:30pm CET (I:30pm GMT/8:30am EST)


Strasbourg, France, March 8, 2016 – Transgene SA (Euronext: TNG) today announced its financial results for the fiscal year ended December 31, 2015 and provided an outlook for 2016.

Financial Year 2015 highlights:

• Net cash burn for 2015 decreased by 22.5% to ?34.8 million, versus ?44.9 million in 2014
• Cash available at year-end 2015 were ?31.7 million compared to ?65.9 million at year-end 2014
• R&D expenses of ?32.1 million compared to ?41.7 million in 2014
• Restructuring costs of ?7.5 million in 2015
• Net loss of ?46.4 million in 2015, including restructuring costs, compared to ?48.6 million in 2014

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant